Systemic immune challenges trigger and drive Alzheimer-like neuropathology in mice

Journal of Neuroinflammation

Volumn 9, Issue , 2012, Pages

  Krstic, Dimitrije ^a   Madhusudan, Amrita ^a   Doehner, Jana ^a   Vogel, Prisca ^a   Notter, Tina ^a   Imhof, Claudine ^a   Manalastas, Abigail ^a   Hilfiker, Martina ^a   Pfister, Sandra ^a   Schwerdel, Cornelia ^a   Riether, Carsten ^b   Meyer, Urs ^c   Knuesel, Irene ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c ETH ZURICH   (Switzerland)

Author keywords

Aging; Cytokines; Immune challenge; Interleukins; Mouse model of sporadic Alzheimer's disease; Neuroinflammation; PolyI:C; Systemic infection

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; POLYINOSINIC POLYCYTIDYLIC ACID; TAU PROTEIN;

AGING; ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTOSIS; BIOACCUMULATION; CELL ACTIVATION; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE PREDISPOSITION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; IMMUNOSTIMULATION; MEMORY DISORDER; MOUSE; NERVOUS SYSTEM INFLAMMATION; NEUROPATHOLOGY; NONHUMAN; PROTEIN AGGREGATION; PROTEIN PHOSPHORYLATION; PROVOCATION TEST; RISK FACTOR; WORKING MEMORY;

EID: 84862693569     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-9-151     Document Type: Article

References (63)

1. McGeer PL, McGeer EG. Local neuroinflammation and the progression of Alzheimer's disease. J Neurovirol 2002, 8:529-538. 10.1080/13550280290100969, 12476347.
2. Lue LF, Brachova L, Civin WH, Rogers J. Inflammation, Abeta deposition, and neurofibrillary tangle formation as correlates of Alzheimer's disease neurodegeneration. J Neuropathol Exp Neurol 1996, 55:1083-1088.
3. Edison P, Archer HA, Gerhard A, Hinz R, Pavese N, Turkheimer FE, Hammers A, Tai YF, Fox N, Kennedy A, Rossor M, Brooks DJ. Microglia, amyloid, and cognition in Alzheimer's disease: An [11C](R)PK11195-PET and [11C]PIB-PET study. Neurobiol Dis 2008, 32:412-419. 10.1016/j.nbd.2008.08.001, 18786637.
4. Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, Combarros O, Zelenika D, Bullido MJ, Tavernier B, Letenneur L, Bettens K, Berr C, Pasquier F, Fiévet N, Barberger-Gateau P, Engelborghs S, De Deyn P, Mateo I, Franck A, Helisalmi S, Porcellini E, Hanon O, Investigators EA, de Pancorbo MM, Lendon C, Dufouil C, Jaillard C, Leveillard T, Alvarez V, Bosco P, Mancuso M, Panza F, Nacmias B, Bossù P, Piccardi P, Annoni G, Seripa D, Galimberti D, Hannequin D, Licastro F, Soininen H, Ritchie K, Blanché H, Dartigues JF, Tzourio C, Gut I, Van Broeckhoven C, Alpérovitch A, Lathrop M, Amouyel P. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet 2009, 41:1094-1099. 10.1038/ng.439, 19734903.
5. Schmidt R, Schmidt H, Curb JD, Masaki K, White LR, Launer LJ. Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia Aging Study. Ann Neurol 2002, 52:168-174. 10.1002/ana.10265, 12210786.
6. Engelhart MJ, Geerlings MI, Meijer J, Kiliaan A, Ruitenberg A, van Swieten JC, Stijnen T, Hofman A, Witteman JC, Breteler MM. Inflammatory proteins in plasma and the risk of dementia: the Rotterdam study. Arch Neurol 2004, 61:668-672. 10.1001/archneur.61.5.668, 15148142.
7. Wyss-Coray T. Inflammation in Alzheimer disease: driving force, bystander or beneficial response?. Nat Med 2006, 12:1005-1015.
8. Rogers J, Strohmeyer R, Kovelowski CJ, Li R. Microglia and inflammatory mechanisms in the clearance of amyloid beta peptide. Glia 2002, 40:260-269. 10.1002/glia.10153, 12379913.
9. Griffin WS, Stanley LC, Ling C, White L, MacLeod V, Perrot LJ, White CL, Araoz C. Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci USA 1989, 86:7611-7615. 10.1073/pnas.86.19.7611, 298116, 2529544.
10. Sheng JG, Ito K, Skinner RD, Mrak RE, Rovnaghi CR, Van Eldik LJ, Griffin WS. In vivo and in vitro evidence supporting a role for the inflammatory cytokine interleukin-1 as a driving force in Alzheimer pathogenesis. Neurobiol Aging 1996, 17:761-766. 10.1016/0197-4580(96)00104-2, 8892349.
11. Mrak RE, Griffin WS. Glia and their cytokines in progression of neurodegeneration. Neurobiol Aging 2005, 26:349-354. 10.1016/j.neurobiolaging.2004.05.010, 15639313.
12. McGeer PL, Schulzer M, McGeer EG. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology 1996, 47:425-432. 10.1212/WNL.47.2.425, 8757015.
13. Aisen PS, Schafer KA, Grundman M, Pfeiffer E, Sano M, Davis KL, Farlow MR, Jin S, Thomas RG, Thal LJ, . Alzheimer's Disease Cooperative Study Effects of rofecoxib or naproxen versus placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 2003, 289:2819-2826. 10.1001/jama.289.21.2819, 12783912, Alzheimer's Disease Cooperative Study.
14. Soininen H, West C, Robbins J, Niculescu L. Long-term efficacy and safety of celecoxib in Alzheimer's disease. Dement Geriatr Cogn Disord 2007, 23:8-21. 10.1159/000096588, 17068392.
15. Thal LJ, Ferris SH, Kirby L, Block GA, Lines CR, Yuen E, Assaid C, Nessly ML, Norman BA, Baranak CC, Reines SA, . Rofecoxib Protocol 078 study group A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology 2005, 30:1204-1215. 10.1038/sj.npp.1300690, 15742005, Rofecoxib Protocol 078 study group.
16. Breitner JC, Baker LD, Montine TJ, Meinert CL, Lyketsos CG, Ashe KH, Brandt J, Craft S, Evans DE, Green RC, Ismail MS, Martin BK, Mullan MJ, Sabbagh M, Tariot PN, . ADAPT Research Group Extended results of the Alzheimer's disease anti-inflammatory prevention trial. Alzheimers Dement 2011, 7:402-411. 10.1016/j.jalz.2010.12.014, 3149804, 21784351, ADAPT Research Group.
17. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 2001, 413:732-738. 10.1038/35099560, 11607032.
18. Cunningham C, Campion S, Teeling J, Felton L, Perry VH. The sickness behaviour and CNS inflammatory mediator profile induced by systemic challenge of mice with synthetic double-stranded RNA (PolyI:C). Brain Behav Immun 2007, 21:490-502. 10.1016/j.bbi.2006.12.007, 17321719.
19. Meyer U, Nyffeler M, Engler A, Urwyler A, Schedlowski M, Knuesel I, Yee BK, Feldon J. The time of prenatal immune challenge determines the specificity of inflammation-mediated brain and behavioral pathology. J Neurosci 2006, 26:4752-4762. 10.1523/JNEUROSCI.0099-06.2006, 16672647.
20. Meyer U, Nyffeler M, Yee BK, Knuesel I, Feldon J. Adult brain and behavioral pathological markers of prenatal immune challenge during early/middle and late fetal development in mice. Brain Behav Immun 2008, 22:469-486. 10.1016/j.bbi.2007.09.012, 18023140.
21. Knuesel I, Nyffeler M, Mormède C, Muhia M, Meyer U, Pietropaolo S, Yee BK, Pryce CR, LaFerla FM, Marighetto A, Feldon J. Age-related accumulation of Reelin in amyloid-like deposits. Neurobiol Aging 2009, 30:697-716. 10.1016/j.neurobiolaging.2007.08.011, 17904250.
22. Knuesel I. Reelin-mediated signaling in neuropsychiatric and neurodegenerative diseases. Prog Neurobiol 2010, 91:257-274. 10.1016/j.pneurobio.2010.04.002, 20417248.
23. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y, LaFerla FM. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 2003, 39:409-421. 10.1016/S0896-6273(03)00434-3, 12895417.
24. Deacon RM, Bannerman DM, Kirby BP, Croucher A, Rawlins JN. Effects of cytotoxic hippocampal lesions in mice on a cognitive test battery. Behav Brain Res 2002, 133:57-68. 10.1016/S0166-4328(01)00451-X, 12048174.
25. Paxinos G, Franklin K. The mouse brain in stereotaxic coordinates 2001, San Diego: Academic, 2.
26. Doehner J, Madhusudan A, Konietzko U, Fritschy JM, Knuesel I. Co-localization of Reelin and proteolytic AbetaPP fragments in hippocampal plaques in aged wild-type mice. J Alzheimers Dis 2010, 19:1339-1357.
27. Kocherhans S, Madhusudan A, Doehner J, Breu KS, Nitsch RM, Fritschy JM, Knuesel I. Reduced Reelin expression accelerates amyloid-beta plaque formation and tau pathology in transgenic Alzheimer's disease mice. J Neurosci 2010, 30:9228-9240.
28. Knuesel I, Riban V, Zuellig RA, Schaub MC, Grady RM, Sanes JR, Fritschy JM. Increased vulnerability to kainate-induced seizures in utrophin-knockout mice. Eur J Neurosci 2002, 15:1474-1484. 10.1046/j.1460-9568.2002.01980.x, 12028357.
29. Schnell SA, Staines WA, Wessendorf MW. Reduction of lipofuscin-like autofluorescence in fluorescently labeled tissue. J Histochem Cytochem 1999, 47:719-730. 10.1177/002215549904700601, 10330448.
30. Pimplikar SW, Suryanarayana A. Detection of APP intracellular domain in brain tissue. Methods Mol Biol 2011, 670:85-91.
31. Anisman H, Gibb J, Hayley S. Influence of continuous infusion of interleukin1-beta on depression-related processes in mice: corticosterone, circulating cytokines, brain monoamines, and cytokine mRNA expression. Psychopharmacology 2008, 199:199-244. 10.1007/s00213-008-1157-0, 3480084, 18470505.
32. Hanisch UK, Kettenmann H. Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat Neurosci 2007, 10:1387-1394. 10.1038/nn1997, 17965659.
33. Ghosal K, Stathopoulos A, Pimplikar SW. APP intracellular domain impairs adult neurogenesis in transgenic mice by inducing neuroinflammation. PLoS One 2010, 5:e11866. 10.1371/journal.pone.0011866, 2912762, 20689579.
34. Hoover BR, Reed MN, Su J, Penrod RD, Kotilinek LA, Grant MK, Pitstick R, Carlson GA, Lanier LM, Yuan LL, Ashe KH, Liao D. Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. Neuron 2010, 68:1067-1081. 10.1016/j.neuron.2010.11.030, 3026458, 21172610.
35. Perry VH, Nicoll JA, Holmes C. Microglia in neurodegenerative disease. Nat Rev Neurol 2010, 6:193-201. 10.1038/nrneurol.2010.17, 20234358.
36. Rossi D, Volterra A. Astrocytic dysfunction: insights on the role in neurodegeneration. Brain Res Bull 2009, 80:224-232. 10.1016/j.brainresbull.2009.07.012, 19631259.
37. Fuller S, Steele M, Münch G. Activated astroglia during chronic inflammation in Alzheimer's disease-do they neglect their neurosupportive roles?. Mutat Res 2010, 690:40-49. 10.1016/j.mrfmmm.2009.08.016, 19748514.
38. Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 1991, 82:239-259. 10.1007/BF00308809, 1759558.
39. Grammas P, Yamada M, Zlokovic B. The cerebromicrovasculature: a key player in the pathogenesis of Alzheimer's disease. J Alzheimers Dis 2002, 4:217-223.
40. Weller RO, Preston SD, Subash M, Carare RO. Cerebral amyloid angiopathy in the aetiology and immunotherapy of Alzheimer disease. Alzheimers Res Ther 2009, 1:6. 10.1186/alzrt6, 2874258, 19822028.
41. Arnaud L, Robakis NK, Figueiredo-Pereira ME. It may take inflammation, phosphorylation and ubiquitination to 'tangle' in Alzheimer's disease. Neurodegener Dis 2006, 3:313-319. 10.1159/000095638, 16954650.
42. Holmes C, Cunningham C, Zotova E, Culliford D, Perry VH. Proinflammatory cytokines, sickness behavior, and Alzheimer disease. Neurology 2011, 77:212-218. 10.1212/WNL.0b013e318225ae07, 3136056, 21753171.
43. Herbomel P, Thisse B, Thisse C. Zebrafish early macrophages colonize cephalic mesenchyme and developing brain, retina, and epidermis through a M-CSF receptor-dependent invasive process. Dev Biol 2001, 238:274-288. 10.1006/dbio.2001.0393, 11784010.
44. Ginhoux F, Greter M, Leboeuf M, Nandi S, See P, Gokhan S, Mehler MF, Conway SJ, Ng LG, Stanley ER, Samokhvalov IM, Merad M. Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science 2010, 330:841-845. 10.1126/science.1194637, 20966214.
45. Colton CA, Chernyshev ON, Gilbert DL, Vitek MP. Microglial contribution to oxidative stress in Alzheimer's disease. Ann N Y Acad Sci 2000, 99:292-307.
46. Flanary BE, Streit WJ. Progressive telomere shortening occurs in cultured rat microglia, but not astrocytes. Glia 2004, 45:75-88. 10.1002/glia.10301, 14648548.
47. Yun HJ, Yoon JH, Lee JK, Noh KT, Yoon KW, Oh SP, Oh HJ, Chae JS, Hwang SG, Kim EH, Maul GG, Lim DS, Choi EJ. Daxx mediates activation-induced cell death in microglia by triggering MST1 signalling. EMBO J 2011, 30:2465-2476. 10.1038/emboj.2011.152, 3116283, 21572393.
48. Streit WJ, Braak H, Xue QS, Bechmann I. Dystrophic (senescent) rather than activated microglial cells are associated with tau pathology and likely precede neurodegeneration in Alzheimer's disease. Acta Neuropathol 2009, 118:475-485. 10.1007/s00401-009-0556-6, 2737117, 19513731.
49. Buxbaum JD, Oishi M, Chen HI, Pinkas-Kramarski R, Jaffe EA, Gandy SE, Greengard P. Cholinergic agonists and interleukin 1 regulate processing and secretion of the Alzheimer beta/A4 amyloid protein precursor. Proc Natl Acad Sci USA 1992, 89:10075-10078. 10.1073/pnas.89.21.10075, 50280, 1359534.
50. Liu L, Aboud O, Jones RA, Mrak RE, Griffin ST, Barger SW. Apolipoprotein E expression is elevated by interleukin 1 and other interleukin 1-induced factors. J Neuroinflammation 2011, 8:175. 10.1186/1742-2094-8-175, 3286434, 22171672.
51. Li Y, Liu L, Barger SW, Griffin WS. Interleukin-1 mediates pathological effects of microglia on tau phosphorylation and on synaptophysin synthesis in cortical neurons through a p38-MAPK pathway. J Neurosci 2003, 23:1605-1611.
52. Lahiri DK, Maloney B, Zawia NH. The LEARn model: an epigenetic explanation for idiopathic neurobiological diseases. Mol Psychiatry 2009, 14:992-1003. 10.1038/mp.2009.82, 19851280.
53. Johnston H, Boutin H, Allan SM. Assessing the contribution of inflammation in models of Alzheimer's disease. Biochem Soc Trans 2011, 39:886-890. 10.1042/BST0390886, 21787318.
54. Streit WJ. Microglia and Alzheimer's disease pathogenesis. J Neurosci Res 2004, 77:1-8. 10.1002/jnr.20093, 15197750.
55. Jankowsky JL, Younkin LH, Gonzales V, Fadale DJ, Slunt HH, Lester HA, Younkin SG, Borchelt DR. Rodent A beta modulates the solubility and distribution of amyloid deposits in transgenic mice. J Biol Chem 2007, 282:22707-22720. 10.1074/jbc.M611050200, 17556372.
56. Kyrkanides S, Tallents RH, Miller JH, Olschowka ME, Johnson R, Yang M, Olschowka JA, Brouxhon SM, O'Banion MK. Osteoarthritis accelerates and exacerbates Alzheimer's disease pathology in mice. J Neuroinflammation 2011, 8:112. 10.1186/1742-2094-8-112, 3179730, 21899735.
57. van Groen T, Kiliaan AJ, Kadish I. Deposition of mouse amyloid beta in human APP/PS1 double and single AD model transgenic mice. Neurobiol Dis 2006, 23:653-662. 10.1016/j.nbd.2006.05.010, 16829076.
58. Brunden KR, Trojanowski JQ, Lee VM. Evidence that non-fibrillar tau causes pathology linked to neurodegeneration and behavioral impairments. J Alzheimers Dis 2008, 14:393-399. 2789426, 18688089.
59. Selkoe DJ. The molecular pathology of Alzheimer's disease. Neuron 1991, 6:487-498. 10.1016/0896-6273(91)90052-2, 1673054.
60. Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science 1992, 256:184-185. 10.1126/science.1566067, 1566067.
61. Herrup K. Reimagining Alzheimer's disease-an age-based hypothesis. J Neurosci 2010, 30:16755-16762. 10.1523/JNEUROSCI.4521-10.2010, 3004746, 21159946.
62. Spillantini MG, Goedert M. Tau protein pathology in neurodegenerative diseases. TINS 1998, 21:428-433.
63. Porzig R, Singer D, Hoffman R. Epitope mapping of mAbs AT8 and Tau5 directed against hyperphosphorylated regions of the human tau protein. Biochem Biophys Res Commun 2007, 358:644-649. 10.1016/j.bbrc.2007.04.187, 17499212.